An RNA replicon system to investigate promising inhibitors of feline coronavirus.

An RNA replicon system to investigate promising inhibitors of feline coronavirus.

Publication date: Jan 18, 2024

FIPV is of great significance in the cat population around the world, causing 0. 3%-1. 4% of feline deaths in veterinary practices (2). As there are neither effective preventive measures nor approved treatment options available, there is an urgent need to identify antiviral drugs against FIPV. Our FCoV replicon system provides a valuable tool for drug discovery in vitro. Due to the lack of cell culture systems for serotype I FCoVs (the serotype most prevalent in the feline population) (2), a different system is needed to study these viruses. A viral replicon system is a valuable tool for studying FCoVs. Overall, our results demonstrate the utility of the serotype I feline coronavirus replicon system for antiviral screening as well as to study this virus in general. We propose several compounds representing promising candidates for future clinical trials and ultimately with the potential to save cats suffering from FIP.

Concepts Keywords
Antiviral antiviral agents
Cats feline coronavirus
Coronavirus feline infectious peritonitis
Valuable replicon
Veterinary

Semantics

Type Source Name
disease VO population
disease VO effective
disease VO LACK
disease IDO cell
disease VO Viruses
disease MESH feline infectious peritonitis

Original Article

(Visited 1 times, 1 visits today)